Purchase Order 75N93023P01146

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $249,243.54 firm fixed price purchase order to Genscript USA Inc. on August 27, 2023, for gene production and protein expression services. The contract, which was completed on August 26, 2024, encompasses gene synthesis, cloning, plasmid preparation, protein expression, and purification services to support NIAID's research initiatives. This was a sole source negotiated contract with no set-aside designation, awarded under the statutory authority of 41 U.S.C. 1901(a)(1), which permits contracts when only one responsible source can satisfy agency requirements. The work was performed at Genscript's facility in Piscataway, New Jersey, though the services supported research efforts based in Bethesda, Maryland.

Genscript USA Inc., a biotechnology company headquartered in Piscataway, New Jersey, specializes in molecular biology services and has established itself as a critical federal vendor for life sciences and biomedical research. The company provides a comprehensive range of scientific offerings including gene editing, protein production, and antibody development, and maintains an extensive contracting history with multiple federal agencies including the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, and Department of Agriculture. This NIAID award reflects continuity of protocol and ongoing research requirements, leveraging Genscript's demonstrated capability and expertise in supporting federal infectious disease and immunology research initiatives.